Show results for
Refine by
Covid Trial Articles & Analysis
20 news found
Plans were outlined for moving forward in the coming summer towards clinical trials in Australia of the antigen preparation together with a powerful adjuvant (a compound that enhances immune reactions in animals and humans). ...
Clinical Trials Alertgy has successfully completed two 3rd party pilot studies, one with Melbourne, Florida based Complete Care and the other with Cleveland Clinic in Cleveland, Ohio. ...
ByAlertgy
“Over the past two years, we have obtained encouraging data on the potential effects of TSC on oxygenation, including the results of our Altitude, TCOM, and COVID-19 Trials. We continue to believe TSC has potential benefits for patients, particularly as an adjuvant treatment to standard of care therapy for hypoxic solid tumors, like glioblastoma ...
ByCervoMed
This allows BioCardia to initiate its First-in-Human Phase I/II trial in adult patients recovering from Acute Respiratory Distress Syndrome (ARDS) due to COVID-19, with trial initiation expected in the third quarter of 2022. The first part of the clinical trial will evaluate increasing doses of the NK1R+ MSCs and the optimal ...
The change to the clinical trial protocol expands the populations able to participate in the Company’s COVIDITY study. ...
ByScancell
“Omicron exposes limitations of antiviral monoclonal antibody therapy in COVID-19 – a clear opportunity for host-cell directed drugs like zapnometinib. Atriva are currently conducting a Phase 2 study in hospitalized patients with moderate-to-severe COVID-19. In this trial, we expect to generate data that will highlight the broad ...
Synairgen plc (LSE: SNG), the respiratory company developing SNG001, a formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces that the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) has halted all patient recruitment in its Phase 2/3 COVID-19 ...
INOVIO 4Q21 and Year-End 2021 Highlights: INO-4800 was observed to provide full maintenance of T cell responses, but significantly decreased levels of antibodies against the Omicron variant in line with results observed with other COVID-19 vaccines. INOVIO plans to seek regulatory approval to amend the primary endpoint of the INNOVATE Phase 3 trial from ...
Synairgen plc (LSE: SNG), the respiratory company developing SNG001, a formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces that the international Phase 3 SPRINTER trial of SNG001 in patients hospitalised with COVID-19 did not meet its primary or key secondary efficacy endpoints. ...
(NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies to deliver oxygen to areas of the body where it is needed most, today announced completion and topline data from the open-label, Phase 1b clinical trial of its novel, diffusion-enhancing therapeutic, trans sodium crocetinate ...
ByCervoMed
Upcoming Milestones: 6-month topline efficacy results from larger ORA-D-013-1 trial expected in 2022 ORA-D-013-2 trial expected to complete enrollment in 2022 Oravax Medical, Inc.: Oral COVID-19 Vaccine In March 2021, we announced the formation of Oravax, a majority owned joint venture, in partnership with Premas Biotech and ...
Department of Defense, the company will conduct a phase 2 clinical trial for a plague vaccine adjuvanted with CpG 1018 which is anticipated to initiate in the second half of 2022. ...
“We are also encouraged by the results of the Hesperidin Covid-19 clinical trial which has recently been submitted for publication. The study concluded that hesperidin could have beneficial effects and may help reduce certain Covid-19 symptoms. The publication further suggested that earlier treatment of longer duration and/or higher dosage ...
(www.ora-vax.com), has screened and enrolled the first participant in a Phase 1 clinical trial of its oral virus-like particle (VLP) COVID-19 vaccine in Johannesburg, South Africa. The open-label trial anticipates enrolling 24 participants who have not received either a COVID-19 vaccine or contracted the virus. Participants will ...
Keirstead’s speaking details are as follows: Keynote: A Fully Personalized COVID-19 Vaccine Made at Point-of-Care When: Wednesday, November 17, 4:00 PM (GMT +8) Location: Virtual – Singapore In his keynote, Dr. Keirstead will share findings from AIVITA’s ongoing trials in COVID-19 and discuss the advantages of a personalized ...
In 2020, fourteen critically ill COVID-19 patients were treated on Emergency Use and Expanded Use INDs at the Providence Saint John’s Health Center, (Santa Monica, California) and ProMedica Hospitals (Toledo, Ohio). ...
The Phase 1B clinical trial (LSV-002), ongoing at the Noguchi Memorial Institute for Medical Research in Accra, Ghana, is the first vaccine clinical trial for Lassa fever to be conducted in West Africa, where the infection is endemic. ...
Peer-reviewed resultsfrom the Adaptive COVID-19 Treatment Trial (ACTT-2) published in the New England Journal of Medicine showed that baricitinib in combination with remdesivir reduces recovery time, improves clinical status and demonstrates a trend towards a decrease in mortality in hospitalised COVID-19 patients with pneumonia. ...
Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced the initiation of a prospective randomized control trial (RTC) utilizing Daxor’s BVA-100 (Blood Volume Analyzer, “BVA”) technology to guide volume treatment in heart failure patients. ...
You might have heard that COVID-19 vaccine trials are underway in Seattle. What exactly is being tested? ...